Hydroxyurea for sickle cell disease in children
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests different ways to start hydroxyurea for children with sickle cell anemia. The goal is to find the safest and most effective approach to help manage symptoms and prevent complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has sickle cell anemia (HbSS) or sickle-β0-thalassemia (HbSβ0)
- Age 6 months or older
- You and your doctor have decided to start hydroxyurea treatment
- Not currently receiving regular blood transfusions
- Not having sickle-hemoglobin C disease (HbSC) or sickle-β+-thalassemia (HbSβ+)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
This trial checks whether monitoring hydroxyurea drug levels in the blood can help doctors find the best dose for sickle cell patients. It focuses on people with HbSS who have recently had a pain crisis or whose current dose isn't working.
This trial tests a new twice-daily liquid form of hydroxyurea (a common SCD medicine) in children ages 9 months to 11 years with sickle cell disease. It will check how the medicine works in the body, if it is safe, and if it helps reduce pain crises and other complications.
This study tests how well a higher dose of hydroxyurea works for teenagers with sickle cell anemia living in areas where malaria is common. It looks at safety and how the treatment affects their daily lives.
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
Hear when a new Sickle Cell Anemia (HbSS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.